The goal is to treat familial dysautonomia patients with a single injection.
On Thursday, 2119 stocks advanced, 1842 declined and 106 remained unchanged, with an advance decline ratio of 1.15 on the ...
Stealth BioTherapeutics Announces PDUFA Action Date Extension for Elamipretide to Treat Patients with Barth Syndrome ...
The NPI-001 (N-acetylcysteine amide) tablets are a proprietary investigational therapy for the treatment of patients with ...
Zydus has announced that the USFDA has granted Orphan Drug Designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for ...
Ahmedabad: Zydus, a discovery-based, global pharmaceutical company has announced that the U.S. Food and Drug Administration ...
Zai Lab Limited (ZLAB) announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation or ODD to ZL-1310, a ...
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ZL-1310, a potential highly active first-in-class ...
Insilico Medcine( "Insilico") , a clinical stage generative artificial intelligence (AI)-driven biotechnology company today announced the first patient has been dosed in the global multicenter Phase I ...
Nuvalent, Inc. shares have fallen approximately 30% after promising updates on its two lead NSCLC candidates rallied the ...
Hosted on MSN18h
FDA breakthrough status for Bluejay’s CHD therapy brelovitugBreakthrough therapy designation recognises the potential of brelovitug to transform the lives of people living with CHD. We ...
The FDA has granted fast-track designation to an investigational antisense oligonucleotide to treat individuals with myotonic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback